Join
Live feed
·
PRReleasevia Quantisnow
Edgewise Therapeutics Inc. logo

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

ByQuantisnow·Wall Street's wire, on your screen.
EWTX· Edgewise Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EWTX (Edgewise Therapeutics Inc.) and more on Quantisnow.